Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in ...

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia ...

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.